Requirement of NOX2 expression in both retina and bone marrow for diabetes-induced retinal vascular injury

PLoS One. 2013 Dec 17;8(12):e84357. doi: 10.1371/journal.pone.0084357. eCollection 2013.

Abstract

Objective: Diabetic retinopathy, a major cause of blindness, is characterized by increased expression of vascular endothelial growth factor (VEGF), leukocyte attachment to the vessel walls and increased vascular permeability. Previous work has shown that reactive oxygen species (ROS) produced by the superoxide generating enzyme NOX2/NADPH oxidase play a crucial role in the vascular pathology. The aim of this work was to identify the cellular sources of the damaging NOX2 activity by studies using bone marrow chimera mice.

Methods: Bone marrow cells were collected from the femurs and tibias of wild type and NOX2 deficient (NOX2(-/-)) donor mice and injected intravenously into lethally irradiated NOX2(-/-) and wild type recipients. Following recovery from radiation, mice were rendered diabetic by streptozotocin injections. The following groups of bone marrow chimeras were studied: non-diabetic WT → WT, diabetic WT → WT, diabetic WT → NOX2(-/-), diabetic NOX2(-/-) → WT. After 4 weeks of diabetes, early signs of retinopathy were examined by measuring ROS, expression of VEGF and ICAM-1, leukocyte attachment to the vessel wall and vascular permeability.

Results: The retinas of the diabetic WT → WT chimeras showed significant increases in ROS as compared with the non-diabetic chimeras. These diabetes-induced alterations were correlated with increases in expression of VEGF and ICAM-1, leukocyte adhesion and vascular permeability. Each of these diabetes-induced alterations were significantly attenuated in the diabetic WT → NOX2(-/-) and NOX2(-/-) → WT chimera groups (p<0.05).

Conclusion: NOX2-generated ROS produced by both bone marrow-derived cells and resident retinal cells contribute importantly to retinal vascular injury in the diabetic retina. Targeting NOX2 in bone marrow and/or retinal cells may represent a novel therapeutic strategy for the treatment/prevention of vascular injury in the diabetic retina.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Blood-Retinal Barrier / metabolism
  • Blood-Retinal Barrier / pathology
  • Bone Marrow / metabolism*
  • Cell Adhesion
  • Chimera
  • Diabetes Mellitus, Experimental
  • Diabetic Retinopathy / genetics*
  • Diabetic Retinopathy / metabolism
  • Diabetic Retinopathy / pathology
  • Gene Expression*
  • Genotype
  • Intercellular Adhesion Molecule-1 / metabolism
  • Leukocyte Common Antigens / metabolism
  • Leukocytes / metabolism
  • Male
  • Membrane Glycoproteins / genetics*
  • Membrane Glycoproteins / metabolism
  • Mice
  • Mice, Knockout
  • NADPH Oxidase 2
  • NADPH Oxidases / genetics*
  • NADPH Oxidases / metabolism
  • Oxidative Stress / genetics
  • Peroxynitrous Acid / biosynthesis
  • Retina / metabolism*
  • Tyrosine / metabolism
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Membrane Glycoproteins
  • Vascular Endothelial Growth Factor A
  • Intercellular Adhesion Molecule-1
  • Peroxynitrous Acid
  • Tyrosine
  • Cybb protein, mouse
  • NADPH Oxidase 2
  • NADPH Oxidases
  • Leukocyte Common Antigens